Chemomab is a clinical stage biotechnology company developing innovative therapeutics for fibro- inflammatory diseases with high unmet need. Based on the unique role of the soluble protein CCL24 in promoting fibrosis and inflammation, Chemomab developed nebokitug (CM-101), a first-in-class dual activity monoclonal antibody that neutralizes CCL24 and has demonstrated disease-modifying potential. In clinical and preclinical studies, nebokitug has been shown to have a favorable safety profile and has been gene ...

Core Insights - The SPRING trial data presented at Digestive Disease Week 2025 indicates that nebokitug is well-tolerated and shows significant improvements in multiple biomarkers related to fibrotic and inflammatory diseases, suggesting its potential as a first-in-class treatment for primary sclerosing cholangitis (PSC) [1][2][4] Group 1: Clinical Trial Results - The Phase 2 SPRING trial data demonstrated that nebokitug was safe and well-tolerated over a 48-week treatment period, with a safety profile comparable to placebo [2][3] - Nebokitug exhibited dose-dependent anti-inflammatory, anti-fibrotic, and anti-cholestatic effects, particularly in patients with moderate to severe disease, showing sustained improvements in biomarkers associated with disease progression [2][3] - In the open-label extension of the study, patients receiving nebokitug for up to 48 weeks showed continual improvement in fibrosis markers and stabilization of liver stiffness, especially at the 20 mg/kg dose [3] Group 2: Company Overview and Future Plans - Chemomab Therapeutics is a clinical-stage biotechnology company focused on developing innovative therapeutics for fibro-inflammatory diseases, with nebokitug being a dual activity monoclonal antibody targeting CCL24 [8] - The company is preparing for a potential Phase 3 trial for nebokitug based on positive results from the Phase 2 SPRING trial, which has received FDA and EMA Orphan Drug and FDA Fast Track designations for PSC treatment [8] - The Phase 3 trial design aims for a single pivotal trial with a clinical event primary endpoint, providing a streamlined pathway to potential full regulatory approval [8]